High-grade gliomas are among the most lethal of all cancers. Despite considerable advances in multimodality treatment, including surgery, radiotherapy and chemotherapy, the overall prognosis for patients with this disease remains dismal. Currently available treatments necessitate the development of more effective tumor-selective therapies. The use of gene therapy for malignant gliomas is promising, as it allows in situ delivery and selectively targets brain tumor cells while sparing the adjacent normal brain tissue. Viral vectors that deliver proapoptotic genes to malignant glioma cells have been investigated. Although tangible results on patients' survival remain to be further documented, significant advances in therapeutic gene transfer strategies have been made. Recently, cell-based gene delivery has been sought as an alternative method. In this paper, we report the proapoptotic effects of embryonic stem cell (ESC)-mediated mda-7/IL-24 delivery to malignant glioma cell lines. Our data show that these are similar to those observed using a viral vector. In addition, acknowledging the heterogeneity of malignant glioma cells and their signaling pathways, we assessed the effects of conventional treatment for high-grade gliomas, ionizing radiation and temozolomide, when combined with ESC-mediated transgene delivery. This combination resulted in synergistic effects on tumor cell death. The mechanisms involved in this beneficial effect included activation of both apoptosis and autophagy. Our in vitro data support the concept that ESC-mediated gene delivery might offer therapeutic advantages over standard approaches to malignant gliomas. Our results corroborate the theory that combined treatments exploiting different signaling pathways are needed to succeed in the treatment of malignant gliomas.
Introduction
Primary malignant brain tumors are relatively uncommon and yet they are one of the most lethal forms of cancer. Glioblastoma multiforme (GBM) is the most common and aggressive type of primary brain tumor. 1 In children, it is the second most common malignancy after leukemia and represents the leading cause of cancer death in children under the age of 15 years. 2 In adults, GBMs account for B50% of primary brain tumors. 3 Aggressive multimodality treatments with surgery, radiation and chemotherapy have led to some improvement in prognosis for patients with glioblastoma and high-grade gliomas. Recent evidencebased class IIb clinical data support the concept that aggressive surgical resection of GBM has a positive impact on survival. 4 However, the 5-year survival rate of patients with GBM is o5%, with a median survival rate of o12 months. 1 The futility of present treatments in combating this disease is in part due to their inability to address the highly invasive nature of these neoplasms. Malignant cells intersperse themselves with normal brain parenchyma and typically give rise to tumor recurrence in close proximity of the operated surgical site. 5 The strategy of targeting these tumor cells while sparing normal cells may prove to be critical for the success of any potential therapeutics.
Gene therapy strategies currently in clinical trials use viral vectors to deliver therapeutic transgenes directly to normal and tumor cells within the central nervous system (CNS). To date, however, none of these trials have shown a significant clinical benefit. 6 This can be attributed in part to the theoretical and practical limitations of viral vectors, including limited diffusion into brain parenchyma, poor transfection of some cell types, antigenicity and insertional mutagenesis with the potential to cause new tumors. 7 The use of genetically modified cells to deliver gene therapy to the central nervous system may avoid some of these limitations. 8 Embryonic stem cells (ESC) are totipotent cells obtained from the inner cell mass of the blastocyst stage embryo. 9 They have unlimited proliferative capacity. ESC-derived astrocytes have potential advantages over other types of genetically engineered neural cells, such as neuronal progenitor cells. First, astrocytes are fully differentiated unlike pluripotent neuronal progenitor cells that could theoretically differentiate into functional neurons and interfere with existing neural circuits. Second, unlike neuronal progenitor cells, ESCs can be permanently genetically modified using homologous recombination rather than potentially hazardous or transiently expressed viral vectors. Finally, ESCs have unlimited proliferative capacity; if stocks of undifferentiated human ESCs of various human leukocyte antigen types are established in the future, an unlimited supply of immunologically matched cells for transplantation would be available. We have shown that we can differentiate ESCs in a pure astrocytic population, 9 and these maintain migratory capacity. 10 In addition, we have shown that we can engineer ESC-derived astrocytes to express a proapoptotic gene under tight control of a tet-on promoter.
In this study, we show that we can engineer ESCderived astrocytes to conditionally express mda-7/IL-24, a proapotptotic gene shown to have selective effects on cancer cells while sparing the normal tissue. [11] [12] [13] [14] We also show that ESC-mediated gene delivery causes apoptosis in a variety of malignant glioma cell lines, independent of p53 status. Furthermore, our in vitro experiments show that ESC-mediated mda-7/IL-24 delivery causes radiosensitization and overcomes temozolomide (TMZ) resistance. These effects seem to be mediated by interference with signaling pathways of both apoptosis and autophagy.
Materials and methods

Cell lines and cultures
Human malignant glioma cells. Six cell lines were used for these in vitro experiments: U87, U251, U343, U373, A172 and T98G. Cells were cultured in standard condition. In brief, human malignant glioma cell lines U87, A172 and U343 were obtained from the Neurosurgery Tissue Bank (San Francisco, CA), and T98G, U251 and U373 cell lines were obtained from the American Type Culture Collection (ATCC) (Rockville, MD). Cells were cultured in Dulbecco's modified essential medium (Cellgro, Manassas, VA) supplemented with 10% fetal calf serum at 37 1C in an incubator supplemented with 5% CO 2 .
Mouse ESCs. These were passaged and maintained according to previously published protocols. 9 Mouse Ainv-18 ESCs (a gift from Michael Kyba) constitutively express a doxycyclin (Dox)-binding transcriptional activator fusion protein and include a Dox-responsive promoter upstream of a Lox cloning site. Genes cloned into the Lox site using Cre-assisted recombination are then expressed when cells are exposed to Dox (Sigma, St Louis, MO). ESCs were directed to differentiate into astrocytes using protocols recently developed in our lab.
9,10
Engineering of ESC-derived astrocytes conditionally expressing mda-7/IL-24 A complementary DNA containing the entire coding sequence of mda-7/IL-24 (Dr Paul B. Fisher, Virginia Commonwealth University, Richmond, VA) was cloned into the pLox vector as previously described.
3 mda-7-pLox plasmid DNA and Cre recombinase-expressing helper plasmid DNA were prepared using a column purification system (Qiagen, Valencia, CA) and electroporated into appropriately prepared Ainv-18 mouse ESCs. Electroporated Ainv-18 cells were plated onto drug-resistant embryonic feeder cells, and recombinant clones were selected with increasing concentrations of G418. Individual G418-resistant colonies were selected and expanded. Insertion of transgene into the Lox cloning site was confirmed using PCR from a genomic DNA template. 
Cell migration and transwell experiments
To assess the migratory capacity of ESC-derived astrocytes conditionally expressing mda-7/IL-24, transwell experiments were conducted according to published protocols. 15 For these experiments, ESC-derived astrocytes conditionally expressing mda-7/IL-24 (cells 10 5 ) were placed in the upper well (6.5 mm; Corning Inc., Corning, NY) of transwell plates with a porous polycarbonate membrane (8 mm pores) coated with 0.1% gelatin. Glioma cells U87 (5 Â 10 4 cells per well) were placed in the lower wells and incubated in Dulbecco's modified essential medium þ 10% serum. At 24 and 48 h after plating, migration of ESC-derived astrocytes was determined by fixing the membrane, staining the cells using the Hema3 staining kit (Fisher Diagnostics, Pittsburgh, PA), directly counting the number of migrated cells in 10 high-power fields and calculating the mean. Experiments were carried out in triplicate.
RT-PCR, immunocytochemistry, ELISA, FACS for detection of transgene expression Reverse transcriptase-PCR (RT-PCR) analysis. Gene expression was analyzed by RT-PCR. Total RNA was extracted and RT-PCR was performed as previously described. 9 In brief, ESC-derived astrocytes conditionally expressing mda-7/IL-24 were cultured for 24 h in the presence or absence of 1 mg per ml Dox and harvested for RT-PCR. Total cellular RNA was purified using the RNeasy kit (Qiagen, Valencia, CA), with on-column DNAse treatment. All RNA preparations were spectrophotometrically quantified and examined for degradation using gel electrophoresis before reverse transcription. Reverse transcription was performed on 1 mg of total RNA using the Omniscript Reverse Transcriptase Kit (Promega, Madison, WI) and PDN6 random hexamer primers (Pharmacia, Piscataway, NJ) in a total volume of 20 ml. A total volume of 12.5 ml of PCR mixture contained 0.5 ml of complementary DNA template. All PCR amplifications were carried out for 30 cycles. PCR products were examined on 1.8% agarose gels and photographed using an Eagle Eye II imager (Stratagene, La Jolla, CA).
Immunocytochemistry. Differentiated cells were grown on glass coverslips (Fisher Scientific 0 ,6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA), and examined under fluorescent microscopy using the Openlab imaging system (Improvision, Lexington, MA). Omission of the primary antibody served as negative control.
Enzyme-linked immunosorbent assay (ELISA). The adenovirus-mediated mda (Ad.mda)-7 used for this experiment was kindly provided by Dr Paul B Fisher (Virginia Commonwealth University). The virus was aliquoted and kept in À80 1C until the start of the experiment. U87 cells were plated in a six-well plate and infected with different multiplicity of infections of Ad.vec and Ad.mda-7 the next day. At 24 h after infection, conditioned media were collected and stored at À80 1C until experimental use. ESC-derived astrocytes conditionally expressing mda-7/IL-24 were plated (2 Â 10 5 ) in 0.1% gelatin-coated 12-well plates and cultured in Iscove's modified Dulbecco's media, 15% serum replacement. At 24 h after induction with Dox, supernatants were collected and the MDA-7/IL-24 content was determined with an ELISA test kit (R&D Systems Inc., Minneapolis, MN) according to the manufacturer's protocol. The amounts of MDA-7/IL-24 were quantified on the basis of a standard curve after optical density was measured at 450 nm with a reference of 550 nm on an ELISA reader (Dynex Technologies, Chantilly, VA). The mean values at each time point were then used directly for the analysis reported.
Fluorescence-activated cell sorting (FACS). ESC-derived astrocytes conditionally expressing mda-7/IL-24 and growing in monolayer were trypsinized and then washed with medium containing fetal calf serum. Cells were then centrifuged, resuspended in wash buffer (phosphatebuffered saline, 10% fetal calf serum and 0.01% NaN3) and counted. For flow cytometry, cells sequentially labeled with primary (monoclonal anti-GFAP; Sigma) and human IL-24 (GeneHunter Corp., Nashville, TN) antibodies and appropriate secondary antibodies were counted with a FACS scanner (Calibur, Becton Dickinson, San Jose, CA) and further analyzed with a Cell Quest software package (BD Biosciences, San Diego, CA). A gating technique, with appropriate measurements of forward and side scatter, was used to exclude dead cells and cell aggregates from the sorting, and 5000-10 000 cells were counted per analysis.
Exposure to ionizing radiation (IR), TMZ and clonogenic assays Exposure to IR and clonogenic assays. Human malignant glioma cells were exposed to IR for a total dose of 6 Gy using 137 Cs-irradiater-Model E-0103 (United States Nuclear Corp., Burbank, CA) at a dose rate of 3.312 Gy/min, as previously described. 16 To determine intrinsic cellular radiosensitivity, clonogenic assays were used following established methods. 17 Exponentially growing cells were radiated as described above, then immediately counted, diluted and plated on 60 mm culture dishes. After incubation for 14 days, the plates were stained with cresyl violet (Sigma) for colony counting. Colonies with more than 50 cells were scored, and plating efficiency was determined. To determine the effects of concurrent transgenic mda-7/IL-24 and/or TMZ, glioma cells were exposed to the chosen treatment(s) for 72 h after IR and then plated as above.
Exposure to TMZ. Temozolomide was supplied by Schering-Plough (Kelinworth, NJ) and dissolved in dimethyle sulfoxide (Sigma) in 50 mM stock solution. TMZ was used at a concentration of 100 mmol l À1 , as previously described. 18 Detection, quantification and inhibition of apoptosis and autophagy Apoptosis. For detection of in vivo apoptosis, cells were grown on gelatin-coated chamber slides and apoptosis signal was detected using an ApopTag plus fluorescein in situ apoptosis detection kit (Chemicon International), which is an indirect terminal deoxynucleotidyl transferase dUTP nick end labeling method. All procedures were performed according to the kit protocol. After experiments, cells were mounted on slides with vectashield mounting medium (Vector Laboratories) and images were taken with a Leica fluorescence microscope (Leica, Bannockburn, IL). FACS analysis was used to quantify apoptotic and dead cells, by labeling with Annexin V-Phycoerythrin (PE) to detect early apoptotic cells and with vital dye 7-amino-actinomycin D to detect late apoptotic and necrotic cells (BD Biosciences). 19 Gating with appropriate measurement of forward and side scatter was used to exclude dead cells and cell aggregates from the sorting; 5000-10 000 cells were counted per analysis. Flow cytometry (Calibur) data were further analyzed using the Cell Quest software package (BD Bioscences).
Autophagy. Autophagy is the process of sequestrating cytoplasmic proteins into the lytic component and is characterized by the formation of acidic vesicular organelles. To detect and quantify acidic vesicular organelles in mda-7/IL-24, IR and TMZ-treated cells, we performed vital staining with acridine orange, as previously described. 18 Three days after treatment, cells were stained with acridine orange at a final concentration of 1 mg ml À1 for a period of 15 min, removed from the plate with trypsin-EDTA and collected in phenol red-free growth medium. Green (510-530 nm) and red (4650 nm) fluorescence emission from 10 4 cells illuminated with blue (488 nm) excitation light was measured with a FACS Calibur from Becton Dickinson using CellQuest software.
Inhibition of apoptosis and autophagy. To inhibit autophagy, 1.0 mM 3-methyl adenine was added the next day after addition of TMZ. To inhibit apoptosis, the c-Jun N-terminal kinase (JNK) pathway was chosen and cells were pretreated with 5 mM of JNK-inhibitor SP600125, before exposure to IR.
Groups studied. Autophagy and apoptosis experiments were carried out in human malignant glioma cell lines [U87, U251, U343, U373, A172 and T98G] 48 h after exposure to treatment. Nonengineered ESC-derived astrocytes were used as controls. Commercially available IL24 (50 ng ml
À1
; R&D systems) was tested on the same human glioma cell lines.
Cell viability assay
Effects of autophagy and apoptosis inhibition on cell viability were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell viability assay. Cells were seeded in 96-well tissue culture plates (1.0 Â 10 3 cells per well) and treated the next day as described in figure legends. At the indicated time points, the medium was removed, and fresh medium containing 0.5 mg per ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide was added to each well. Cells were incubated at 37 1C for 4 h and then an equal volume of solubilization solution (0.01 N HCl in 10% sodium dodecyl sulfate) was added to each well and mixed thoroughly. The optical density from the plates was read on an ELISA plate reader at 570 nm.
Western blot analysis
Briefly, for western blotting experiments, cells were harvested in radioimmuno precipitation assay buffer (1% Nonidet P-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate in phosphate-buffered saline) containing protease inhibitor cocktail (Protease Arrest TM; Calbiochem, San Diego, CA), 50 mM NaF and 1 mM Na3VO4, homogenized and centrifuged at 12 000 r.p.m. for 10 min at 4 1C. The supernatant was used as total cell lysate. Protein lysates (30-50 mg) were denatured in 2% sodium dodecyl sulfate, 10 mM dithiothreitol, 60 mM Tris-HCl (pH 6.8) and 0.1% bromphenol blue, and loaded onto a 12% polyacrylamide/sodium dodecyl sulfate gel (Bio-Rad, Hercules, CA). The separated proteins were then transferred by electroblot (80 mA, 2 h) onto a nitrocellulose membrane (Bio-Rad). The membrane was blocked for 1 h at RT in TBS-T (0.1 M Tris-HCl (pH 7.6), 1.37 M NaCl, 0.1% Tween 20) containing 5% nonfat dry milk and incubated overnight at 4 1C in TBS-T containing the primary antibody. The membrane was washed in TBS-T, incubated with the secondary antibody conjugated to horseradish peroxides for 1 h at RT and then washed in TBS-T. The ECL nonradioactive detection system (Amersham Pharmacia Biotech, Buckinghamshire, UK) was used to detect antibody-protein complexes by exposing the membrane to an X-ray film. X-ray films were scanned and bands were densitometrically evaluated by Image J software (NIH, Bethesda, MD).
The following primary antibodies were used: phospho-SAPK/JNK (Thr183/Tyr185) (81E11) rabbit mAb (1:1000), total SAPK/JNK (1:1000) (Cell Signaling Technology, Danvers, MA), mouse monoclonal GADD153 (1:500), mouse monoclonal Bcl-xL (1:500) and rabbit polyclonal Bax (1:1000) (SantaCruz Biotechnology, Santa Cruz, CA) and rabbit polyclonal caspase-3 (1:200) (Chemicon International).
Statistical analysis
All experiments were repeated three times using triplicate samples for cell counting analysis. Data are expressed as mean ± s.d. and were considered significant when Po0.05. The statistical significance of the experimental results was evaluated using Student's t-test. Comparison of the effects of various treatments was carried out using one-way ANOVA. For synergistic analysis, a modified Student's t-test was used.
Results
Engineered ESC-derived astrocytes conditionally express mda-7/IL-24 and maintain 'homing' To overcome the limitations of Ad-mediated gene transfer for the treatment of malignant gliomas, we engineered ESC-derived astrocytes to conditionally express mda-7/ IL-24. Figure 1a shows the schematic diagram of the DNA insertional cassettes. Undifferentiated Ainv-mda-7/ IL-24 ESCs were then differentiated into astrocytes. 9 Eight days after plating, 485% of ESC-derived cells were differentiated and GFAP positive, confirming their astrocytic nature (Figures 1b and c) . ESC-derived astrocytes maintained 'homing' characteristics typical of stem cells, with a 37% migration rate at 48 h (Figure 1d ) and 80% at 4 days (data not shown).
Semiquantitative RT-PCR (Figure 2a ) and immunohistochemistry (Figure 2b ) performed after Dox induction showed expression of mda-7/IL-24 by ESC-derived astrocytes. Quantification by FACS showed conditional expression of mda-7/IL-24 in 480% of ESC-derived astrocytes, and minimal 'leaky' expression in the absence of Dox (Figure 2c) .
To quantify MDA-7/IL-24 secretion by ESC-derived astrocytes after Dox induction, we used ELISA and compared it with the MDA-7/IL-24 level secreted by U87 cells infected with different multiplicity of infections of Ad.mda-7. As shown in Figure 2d , MDA-7/IL-24 secreted by ESC-derived astrocytes conditionally expressing mda-7/IL-24 is comparable to the level secreted by U87 cells infected with Ad.mda-7 (25 plaque-forming units).
ESC-derived astrocytes conditionally expressing mda-7/ IL-24 induce apoptosis in human malignant glioma cells independent of p53 status To assess the proapoptotic effects of transgenic mda-7/ IL-24 transfer; we used six human glioma cell lines (Figure 3a ). These were cocultured with ESC-derived astrocytes conditionally expressing mda-7/IL-24 after Dox induction. Among the cell lines tested, A172, U343 and U87 are wild type p53 (p53wt); and T98, U251 and U373 are mutant p53 (p53mt). In four of the six cell lines, a significant increase in apoptotic rate was found at 24 h after coculture. The ESC-derived astrocyte-mediated mda-7/IL-24 proapoptotic effects were not correlated to the p53 status, as previously reported with Admediated transfer. 11 A similar apoptotic rate was observed in U87 cells (Figure 3b ) treated with either Ad.mda-7 (25 plaque-forming units) or ESC-derived astroyte-mediated mda-7/IL-24, which is in agreement with the level of MDA-7/IL-24 detected by ELISA (Figure 2d ). Commercially available IL24 that was tested on the same human glioma cell lines did not induce any significant cell death. Nonengineered ESC-derived astrocytes, used as controls, did not show cell death when exposed to ESC-derived astrocytes conditionally expressing mda-7/IL24. ESC-mediated mda-7/IL-24 delivery induces growth suppression and radiosensitization, and overcomes temozolomide resistance in malignant glioma cells To assess the effects of ESC-mediated transgene delivery of mda-7/IL-24 on malignant glioma cells, in combination with conventional treatment for GBM, we performed clonogenic assays. For these experiments, we used two cell lines partially resistant to TMZ: U87 (p53wt) and T98 (p53mt) (Figures 3c and d) . Cells were exposed to transgene delivery alone or in combination with TMZ and/or IR. Exposure to each individual treatment resulted in a decrease in survival fraction, ranging from 35 to 48% for U87 cells and from 19 to 35% for T98G cells. Exposure to all three treatments resulted in a significant decrease in survival fraction, compared with each treatment alone or with a combination of two in both glioma cell lines tested (ANOVA, Po0.05). This was not seen in control cells (nonengineered ESC-derived astrocytes). When considering only a combination of two treatments, mda7/IL-24 plus IR resulted in the strongest decrease in survival fraction. The addition of mda7/IL-24 to TMZ resulted in a significant decrease in survival fraction compared with TMZ alone (Po0.05) in both cell lines.
Both apoptosis and autophagy signaling pathways are activated by ESC-mediated mda-7/IL-24 delivery combined with IR and TMZ To study the mechanism(s) responsible for the significant decrease in survival fraction of human malignant glioma cells when IR, TMZ and transgene mda-7/IL-24 were used, we quantified apoptosis, autophagy and their inhibition.
Figures 4a and b show that the apoptotic rate increases significantly when IR is added to transgene mda-7/IL-24 or TMZ. However, a synergistic effect was noted only when IR was combined with transgene mda-7/IL-24 (modified Student's t-test Po0.05). The combination of all three treatments resulted in further enhanced apoptotic effects. Autophagy was significantly increased by TMZ, as previously reported by our group, 18 and also by transgene mda-7/IL-24, although to a lesser extent (Figure 4c) .
To investigate the signaling pathways involved in decreased human glioma cell survival after exposure to each treatment alone or in combination, we performed western blot analysis (Figures 5a and b) . A synergistic increase in CCAAT/enhancer binding protein homologous transcription factor (CHOP/GADD153) was found when all three treatments were used concomitantly compared with each treatment alone or with combinations of two. On the other hand, the decrease in BcL-xL and increase in caspase-3 and Bak/Bax were moderately enhanced. Combination of all three treatments also resulted in a modest activation of phosphorylated JNK compared with the combination of only two treatments. These results suggest that CHOP/GADD153 serves as the common final pathway to apoptosis and autophagy.
To confirm that the decrease in survival fraction is caused by combined activation of autophagy and apoptosis, we inhibited these processes by using 3-methyl adenine, a nonspecific inhibitor of autophagy, and SP600125, an inhibitor of JNK activation, respectively. 20 Quantification of surviving glioma cells was carried out by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The use of SP600125 resulted in a significant increase in cell viability after exposure to transgene mda-7/IL-24 and IR. This was not observed with the other treatments. 3-methyl adenine resulted in a significant increase in cell viability after exposure to TMZ and IR only (Figures 5c and d) .
These results taken together with clonogenic assays suggest that the combination of IR, TMZ and transgene mda-7/IL-24 has a synergistic effect on malignant glioma cell death by activating CHOP/GADD153, which results in activation of both apoptosis and autophagy, as shown in a schematic diagram ( Figure 6 ).
Discussion
Malignant gliomas remain a therapeutic challenge. 21 Substantial progress in gene delivery by viral vectors has being accomplished. Yet, clinical significance for patients with malignant gliomas is still far from being tangible. Therefore, cell-based therapy is being investigated as an alternative to in situ gene delivery. Recent in vitro and in vivo data support the concept that mda-7/IL-24 causes selective tumor cell death while sparing normal cells and make this gene a good candidate for malignant astrocytoma therapy. 11 Recent work that focused on 'targeted' therapy 22 in conjunction with 'standard therapy', such as TMZ and IR, 23 seems to show excellent clinical results. 24 Strategies aimed at targeting multiple mechanisms responsible for cell death are scientifically promising, as GBM cells are very heterogeneous. In this study, we have made a few new in vitro observations that might have an important effect on therapeutic applications for malignant gliomas.
We have shown that we can generate astrocytes from ESCs engineered to carry proapoptotic genes, with conditional expression controlled by administration of Dox. 25 In this paper, we first confirm that we can engineer ESC-derived astrocytes conditionally expressing mda-7/ IL-24 tightly regulated by Dox administration. We then investigate the effects of ESC-mediated mda-7/IL-24 delivery to malignant glioma cells. First, we compared the proapoptotic effects of this gene when delivered by Ad and by ESC-derived astrocytes. Our results show that transgene effects are similar using each of these two delivery methods. To the best of our knowledge, this is the first time that protein expression and proapoptotic effects after transgene delivery have been semiquantitatively compared using viral and cell vectors.
Malignant gliomas, and in particular glioblastoma, are among the most chemoresistant tumors. 26 Current literature supports the concept that combined IR and TMZ, an alkylating oral chemotherapeutic agent, improves outcome 27 and represents the standard of care for patients with high-grade gliomas. 23 Yet, the average survival using IR and TMZ remains dismal, with a 2-year survival of 26.5%. 27, 28 In this study, we combined the use of IR and TMZ with ESC-based transgene delivery of mda-7/IL-24. Our colony survival experiments showed that the combination of these three agents resulted in a significant decrease in survival fraction compared with each treatment alone or with two in combination. It is important to note that, when we looked at the apoptotic rate, the combination of three treatments did not result in synergistic effects. Therefore, we explored autophagy as a possible alternative explanation for programmed cell death. Data from our laboratory and from others had previously shown that TMZ and mda-7/IL-24 induce cell death by autophagy. 18, 29 Semiquantitative analysis of autophagy showed that additive effects, but not synergistic, were obtained when using three treatments together. These results taken together with the clonogenic assay suggested that the significant increase in tumor cell death seen when ESCmediated mda-7/IL-24 delivery is combined with IR and TMZ is based on activation of both apoptosis and autophagy.
To elucidate the mechanism(s) at the basis of the decreased survival observed, we investigated the unfolded protein response changes occurring after 'endoplasmic reticulum stress'. 30, 31 It has been reported that IR, 32 TMZ 33 and mda-7/IL-24 20 induce endoplasmic reticulum stress. In particular, it has been reported that, as a result of endoplasmic reticulum stress induction, all three modalities cause activation of the JNK by phosphorylation to P-JNK. 30, 34 Our study corroborates the evidence that each treatment activated JNK, IR having the strongest effect. When TMZ or transgenic mda-7/IL-24 was combined with IR, further enhanced effects were noted. It is interesting to note, however, that when all three modalities were combined, there was no additive increase in P-JNK. On the other hand, a synergistic increase in expression of CHOP/GADD153 was seen when all three modalities are used. Recent work supports the evidence that CHOP/GADD153 is one of the critical executioners of the proapoptotic arm of the unfolded protein response. 35 In our study, we showed that there is a synergistic increased expression of CHOP/GADD153 when all three modalities are used. On the basis of this finding, we suggest that CHOP/ GADD153 should be considered as the 'common pathway' for both autophagy and apoptosis in programmed cell death, as summarized in our schematic overview in Figure 6 .
The potential detrimental effects of ESC are discussed in the literature. Experimental allotransplantation of undifferentiated ESCs into the brain or other tissues results in teratoma formation in recipient animals. [36] [37] [38] [39] [40] Transplantation of differentiated ESCs prevents teratoma formation in some experimental studies, 41, 42 but not in others. 38, 39 In our animal studies, we have not seen teratoma formation. 10 On the other hand, the use of normal adult glial progenitor cells have the capacity to give rise to malignant gliomas, 43 hindering their use as vectors. Because of the magnitude of these potential side effects, additional studies using both ESC-derived astrocytes and neuronal progenitor cell-derived cells are necessary before these cells can be considered suitable for a clinical trial.
Conclusions
In summary, in this study we made a few new observations that can positively affect future treatment of patients with malignant gliomas. We showed that ESC-mediated proapoptotic gene delivery for human malignant glioma has biological effects similar to that of adviral mediated. In addition, our study supports the concept that the proapoptotic effects of transgene delivery are augmented when combined with conventional therapy currently used for malignant gliomas, i.e., IR and TMZ. Furthermore, our study shows that the activation of autophagy and apoptosis is at the basis of the decreased malignant glioma cell survival when the three treatments are combined. Finally, we suggest that CHOP/GADD 153 serves a common final pathway for both apoptosis and autophagy. This observation has the potential for providing a new 'target' for malignant astrocytoma. proposed as the 'common pathway' to autophagy and apoptosis. IR, ESC-mediated transgene mda-7/IL-24 and TMZ cause endothelial reticulum (ER) stress. 31, 35 This results in JNK phosphorylation, and overexpression of CHOP/GADD153. Overexpression of CHOP/ GADD153 results in induction of proapoptotic proteins Bak/Bax and decreases antiapoptotic proteins BcL-2/Bcl-xL with downstream casapase-3 activation, resulting in apoptosis. Independently, increased expression of CHOP/GADD153 results in increased autophagy.
